Effects of clozapine, olanzapine and haloperidol on nitric oxide production by lipopolysaccharide-activated N9 cells

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 30, Issue 8, 2006, Pages 1523-1528

  Hou, Yue ^a,b   Wu, Chun Fu ^a   Yang, Jing Yu ^a   He, Xiang ^b   Bi, Xiu Li ^a   Yu, Liang ^a   Guo, Tao ^b  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

Author keywords

Clozapine; Haloperidol; N9 cells; Nitric oxide (NO); Olanzapine

Indexed keywords

CLOZAPINE; HALOPERIDOL; LIPOPOLYSACCHARIDE; NITRIC OXIDE; OLANZAPINE;

ANIMAL CELL; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; IN VITRO STUDY; MICROGLIA; NONHUMAN; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CELL LINE; CELL SURVIVAL; CLOZAPINE; HALOPERIDOL; LIPOPOLYSACCHARIDES; MICE; MICROGLIA; NITRIC OXIDE; NITRITES;

EID: 33750337058     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2006.05.006     Document Type: Article

References (47)

1. Akbarian S., Vinuela A., Kim J.J., Potkin S.G., Bunney Jr. W.E., and Jones E.G. Distorted distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase neurons in temporal lobe of schizophrenics implies anomalous cortical development. Arch Gen Psychiatry 50 (1993) 178-187
2. Altar C.A., Wasley A.M., Neale R.F., and Stone G.A. Typical and atypical antipsychotic occupancy of D2 and S2 receptors: an autoradiographic analysis in rat brain. Brain Res Bull 16 (1986) 517-525
3. Aravagiri M., Teper Y., and Marder S.R. Pharmacokinetics and tissue distribution of olanzapine in rats. Biopharm Drug Dispos 20 (1999) 369-377
4. Baba H., Suzuki T., Arai H., and Emson P.C. Expression of nNOS and soluble guanylate cyclase in schizophrenic brain. NeuroReport 15 (2004) 677-680
5. Baldessarini R.J., Centorrino F., Flood J.G., Volpicelli S.A., Huston-Lyons D., and Cohen B.M. Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacology 9 (1993) 117-124
6. Barger S.W., and Harmon A.D. Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature 388 (1997) 878-881
7. Bayer T.A., Buslei R., Havas L., and Falkai P. Evidence for activation of microglia in patients with psychiatric illnesses. Neurosci Lett 271 (1999) 126-128
8. Beasley Jr. C.M., Sanger T., Satterlee W., Tollefson G., Tran P., and Hamilton S. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 124 (1996) 159-167
9. Beasley Jr. C.M., Tollefson G., Tran P., Satterlee W., Sanger T., and Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14 (1996) 111-123
10. Beasley Jr. C.M., Hamilton S.H., Crawford A.M., Dellva M.A., Tollefson G.D., Tran P.V., et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 7 (1997) 125-137
11. Bhana N., Foster R.H., Olney R., and Plosker G.L. Olanzapine: an updated review of its use in the management of schizophrenia. Drugs 61 (2001) 111-161
12. Bi X.L., Yang J.Y., Dong Y.X., Wang J.M., Cui Y.H., Ikeshima T., et al. Resveratrol inhibits nitric oxide and TNF-alpha production by lipopolysaccharide-activated microglia. Int Immunopharmacol 5 (2005) 185-193
13. Black M.D., Simmonds J., Senyah Y., and Wettstein J.G. Neonatal nitric oxide synthase inhibition: social interaction deficits in adulthood and reversal by antipsychotic drugs. Neuropharmacology 42 (2002) 414-420
14. Blin O. A comparative review of new antipsychotics. Can J Psychiatry 44 (1999) 235-244
15. Boyle E.A., and McGeer P.L. Cellular immune response in multiple sclerosis plaques. Am J Pathol 137 (1990) 575-584
16. Buckley P.F. New dimensions in the pharmacologic treatment of schizophrenia and related psychoses. J Clin Pharmacol 37 (1997) 363-378
17. Chang J.Y., Chavis J.A., Liu L.Z., and Drew P.D. Cholesterol oxides induce programmed cell death in microglial cells. Biochem Biophys Res Commun 249 (1998) 817-821
18. Das I., Khan N.S., Puri B.K., Sooranna S.R., de Belleroche J., and Hirsch S.R. Elevated platelet calcium mobilization and nitric oxide synthase activity may reflect abnormalities in schizophrenic brain. Biochem Biophys Res Commun 212 (1995) 375-380
19. Das I., Khan N.S., Puri B.K., and Hirsch S.R. Elevated endogenous nitric oxide synthase inhibitor in schizophrenic plasma may reflect abnormalities in brain nitric oxide production. Neurosci Lett 215 (1996) 209-211
20. Dwyer D.S., Lu X.H., and Bradley R.J. Cytotoxicity of conventional and atypical antipsychotic drugs in relation to glucose metabolism. Brain Res 971 (2003) 31-39
21. Gonzalez-Scarano F., and Baltuch G. Microglia as mediators of inflammatory and degenerative diseases. Annu Rev Neurosci 22 (1999) 219-240
22. Karson C.N., Griffin W.S., Mrak R.E., Husain M., Dawson T.M., Snyder S.H., et al. Nitric oxide synthase (NOS) in schizophrenia: increases in cerebellar vermis. Mol Chem Neuropathol 27 (1996) 275-284
23. Kaul M., Garden G.A., and Lipton S.A. Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 410 (2001) 988-994
24. Kornhuber J., Schultz A., Wiltfang J., Meineke I., Gleiter C.H., Zochling R., et al. Persistence of haloperidol in human brain tissue. Am J Psychiatry 156 (1999) 885-890
25. Lawson L.J., Perry V.H., Dri P., and Gordon S. Heterogeneity in the distribution and morphology of microglia in the normal, adult mouse brain. Neuroscience 39 (1991) 151-170
26. Lee Y., Nagai A., and Kim S. Cytokines, chemokines and cytokine receptors in human microglia. J Neurosci Res 69 (2002) 94-103
27. Li X.M., Chlan-Fourney J., Juorio A.V., Bennett V.L., Shrikhande S., Keegan D.L., et al. Differential effects of olanzapine on the gene expression of superoxide dismutase and the low affinity nerve growth factor receptor. J Neurosci Res 56 (1999) 72-75
28. Lu X.H., Bradley R.J., and Dwyer D.S. Olanzapine produces trophic effects in vitro and stimulates phosphorylation of Akt/PKB, ERK1/2, and the mitogen-activated protein kinase p38. Brain Res 1011 (2004) 58-68
29. 2+-dependently converts l-arginine into an activator of soluble guanylyl cyclase. Biochem Biophys Res Commun 164 (1989) 678-685
30. Mcgeer P., Kawamata T., Walker D., Akiyama H., Tooyama L., and Mcgeer E. Microglia in degenerative neurological disease. Glia 7 (1993) 84-92
31. Meltzer H.Y. Dopamine 2 receptor occupancy and the action of clozapine: does it make a difference to add a neuroleptic?. Biol Psychiatry 46 (1999) 144-149
32. Meltzer H.Y., Matsubara S., and Lee J.C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin 2 pKi values. J Pharmacol Exp Ther 251 (1989) 238-246
33. Munn N.A. Microglia dysfunction in schizophrenia: an integrative theory. Med Hypotheses 54 (2000) 198-202
34. Nel A., and Harvey B.H. Haloperidol-induced dyskinesia is associated with striatal NO synthase suppression: reversal with olanzapine. Behav Pharmacol 14 (2003) 251-255
35. Olesen O.V., and Linnet K. Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication. Ther Drug Monit 21 (1999) 87-90
36. Rasmussen K., and Aghajanian G.K. Potency of antipsychotics in reversing the effects of a hallucinogenic drug on locus coeruleus neurons correlates with 5-HT2 binding affinity. Neuropsychopharmacology 1 (1988) 101-107
37. Robertson M.D., and McMullin M.M. Olanzapine concentrations in clinical serum and postmortem blood specimens-when does therapeutic become toxic?. J Forensic Sci 45 (2000) 418-421
38. Snyder S.H., and Bredt D.S. Nitric oxide as a neuronal messenger. Trends Pharmacol Sci 12 (1991) 125-128
39. Stoll G., and Jander S. The role of microglia and macrophages in the pathophysiology of the CNS. Prog Neurobiol 58 (1999) 233-247
40. Stoppe G., and Staedt J. Psychopharmacotherapy of behavioral disorders in patients with dementia. Z Gerontol Geriatr 32 (1999) 153-158
41. Suzuki E., Nakaki T., Shintani F., Kanba S., and Miyaoka H. Antipsychotic, antidepressant, anxiolytic, and anticonvulsant drugs induce type II nitric oxide synthase mRNA in rat brain. Neurosci Lett 333 (2002) 217-219
42. Tarazi F.I., Zhang K., and Baldessarini R.J. Long-term effects of newer antipsychotic drugs on neuronal nitric oxide synthase in rat brain. Nitric Oxide 7 (2002) 297-300
43. Tollefson G.D., Beasley Jr. C.M., Tran P.V., Street J.S., Krueger J.A., Tamura R.N., et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 154 (1997) 457-465
44. Tran P.V., Hamilton S.H., Kuntz A.J., Potvin J.H., Andersen S.W., Beasley Jr. C., et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 17 (1997) 407-418
45. Wolff M.C., and Leander J.D. Comparison of the effects of antipsychotics on a delayed radial maze task in the rat. Psychopharmacology 168 (2003) 410-416
46. Wolfgang S.A. Olanzapine in whole, not half, tablets for psychosis from Alzheimer's dementia. Am J Health Syst Pharm 56 (1999) 2245-2246
47. Yanik M., Vural H., Kocyigit A., Tutkun H., Zoroglu S.S., Herken H., et al. Is the arginine-nitric oxide pathway involved in the pathogenesis of schizophrenia?. Neuropsychobiology 47 (2003) 61-65